Myriad Genetics, Inc.
MYGN
$10.18
-$0.34-3.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 11.21% | 12.15% | 14.78% | 11.44% | 11.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.21% | 12.15% | 14.78% | 11.44% | 11.03% |
| Cost of Revenue | 6.77% | 11.20% | 12.16% | 13.32% | 16.93% |
| Gross Profit | 13.23% | 12.57% | 16.00% | 10.61% | 8.52% |
| SG&A Expenses | -1.16% | -2.12% | -1.68% | -0.05% | 5.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.74% | 2.63% | 3.01% | 3.77% | 8.07% |
| Operating Income | 36.72% | 39.34% | 41.30% | 28.09% | 5.57% |
| Income Before Tax | 52.94% | 58.65% | 40.91% | -41.19% | -86.49% |
| Income Tax Expenses | 254.55% | 92.11% | 91.67% | 95.63% | 103.85% |
| Earnings from Continuing Operations | 51.65% | 57.73% | 37.47% | -60.47% | -135.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.65% | 57.73% | 37.47% | -60.47% | -135.09% |
| EBIT | 36.72% | 39.34% | 41.30% | 28.09% | 5.57% |
| EBITDA | 67.71% | 64.64% | 56.66% | 37.34% | 12.39% |
| EPS Basic | 56.19% | 61.33% | 40.77% | -56.55% | -131.36% |
| Normalized Basic EPS | 44.22% | 45.31% | 45.32% | 29.45% | 4.34% |
| EPS Diluted | 56.03% | 61.05% | 40.40% | -56.51% | -130.32% |
| Normalized Diluted EPS | 44.22% | 45.31% | 45.32% | 29.45% | 4.34% |
| Average Basic Shares Outstanding | 9.52% | 9.53% | 7.16% | 4.85% | 2.57% |
| Average Diluted Shares Outstanding | 9.52% | 9.53% | 7.16% | 4.85% | 2.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
